Our current approach to treatment involves the utilization of sigma receptor ligands that modulate complex biochemical pathways and are involved in disease manifestation and progression. There is strong pharmacological evidence which indicates that sigma-1 and sigma-2 receptors, at least in part, act as intracellular amplifiers creating a supersensitive state of signal transduction in biochemical pathways in both CNS and cancer.

ANAVEX is positioned with solid-patented sigma ligands and their chemical families and is proceeding to further develop eleven candidates which have exhibited multiple pharmacological profiles suggesting direct or functional links to various aspects of the targeted disease. This enhances the probabilities of successful advancement to market.